Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | EBP | Q15125 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.50 |
| ▸ | TUBB | P07437 | 1/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10411628 | 0.93 | ATM (0.58) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL27200220 | 0.93 | ATM (0.58) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL516206 | 0.88 | ATM (0.66) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL30764700 | 0.88 | ATM (0.66) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL10343404 | 0.88 | ATM (0.70) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL30869991 | 0.88 | ATM (0.70) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL23913120 | 0.86 | ATM (0.68) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL31556187 | 0.86 | ATM (0.68) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL31556190 | 0.86 | ATM (0.68) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL17295274 | 0.85 | ATM (0.44) | ATMKDM4ECA2POLBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4616906-A2 | BENZO[A]PHENANTHRIDINE DERIVATIVES AS YAP/TAZ INHIBITORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20220267277-A1 | DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-08-25 | — | — | US | disclosed |
| EP-4003339-A2 | DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | NAGASE & CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| WO-2021021953-A2 | DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021021953-A2 | DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-2632889-B1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD (IL) | 2018-08-29 | — | — | EP | disclosed |
| WO-2016115360-A1 | C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016115360-A1 | C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-0297733-A2 | Pharmaceutical compositions comprising catecholic butanes | BLOCK DRUG COMPANY, INC. (US) | 1989-01-04 | — | — | EP | disclosed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| EP-0288534-A1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. | CHEMEX PHARMACEUTICALS INC (US) | 1988-11-02 | — | — | EP | disclosed |
| WO-1988003806-A1 | PHARMACOLOGICALLY ACTIVE COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| WO-1988003026-A1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-05-05 | — | — | WO | disclosed |
| US-4733002-A | Lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1988-03-22 | — | — | US | disclosed |
| US-4711895-A | 4-hydroxy-2-cyclopentenone, process for production thereof, pharmaceutical composition comprising it | TEIJIN LIMITED (JP) | 1987-12-08 | — | — | US | disclosed |
| EP-0180399-A2 | Anti-tumor 4-Hydroxy-2-cyclopentenones | TEIJIN LIMITED (JP) | 1986-05-07 | — | — | EP | disclosed |
| EP-0163270-A2 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267277-A1 | DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE | PRLHR, YAP1, MST1R | ATM 1235/4885KDM4E 2956/4885CA2 4844/4885 |
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | VIP, IAPP, RPS27A | ATM 3744/4885KDM4E 4477/4885CA2 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.